Drugs / INT230-6
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03058289 | Feb 2017 → Feb 2023 | bile duct cancer, breast cancer, colorectal cancer, head and neck cancer +6 | Intensity Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06358573 | Oct 2024 → Oct 2028 expected | triple-negative breast carcinoma | Swiss Cancer Institute | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06263231 | Jun 2024 → Dec 2027 expected | soft tissue sarcoma | Intensity Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT 230-6 | “INT 230-6 Combined With Ipilimumab (Cohort FEC)” NCT03058289 ↗ |
| Route | Other | “administered by injection directly into the tumor” NCT03058289 ↗ |